银屑病系统治疗与死亡风险降低:PSOLAR巢式病例对照分析
该研究基于PSOLAR登记数据库,采用巢式病例对照设计,评估系统治疗对银屑病患者死亡风险的影响。共纳入12,090例患者,341例死亡,按1:4匹配1364例对照。结果显示,近3个月内生物制剂暴露与死亡风险降低相关,无论治疗时长;甲氨蝶呤仅在暴露≥1年时显示保护作用。
要点
- 生物制剂近3个月内暴露与死亡风险降低相关,OR为0.08-0.09。
- 甲氨蝶呤仅暴露≥1年时与死亡风险降低相关,OR为0.08。
- 观察性研究存在未测混杂,需谨慎解读因果关联。
核心结论
- 生物制剂治疗与中重度银屑病患者死亡风险降低相关,无论治疗时长。
- 甲氨蝶呤仅在暴露≥1年时与死亡风险降低相关。
研究设计与样本
- 巢式病例对照分析,数据来自PSOLAR登记。
- 共12,090例患者,341例死亡,按1:4匹配1364例对照。
- 匹配因素包括年龄、种族、性别和地理区域。
主要发现
- 近3个月内生物制剂暴露<1年者死亡风险OR为0.08(95%CI 0.03-0.23)。
- 近3个月内生物制剂暴露≥1年者死亡风险OR为0.09(95%CI 0.06-0.13)。
- 甲氨蝶呤暴露≥1年者死亡风险OR为0.08(95%CI 0.02-0.28)。
临床怎么用
- 对于中重度银屑病患者,生物制剂治疗可能与降低死亡风险相关。
- 甲氨蝶呤需持续暴露≥1年才可能观察到死亡风险降低。
局限性
- 观察性研究设计,存在未测混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood. OBJECTIVE: To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry. METHODS: Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in the Psoriasis Longitudinal Assessment and Registry. Cases were matched (1:4) with controls by age, race, sex, and geographic region. Evaluated treatments included methotrexate, ustekinumab, and tumor necrosis factor α inhibitors. Exposure was defined as at least 1 dose of treatment within 3 months before death and was stratified by duration of therapy. RESULTS: Among 12,090 patients, 341 deaths occurred, matched to 1364 controls. Biologic treatment within the preceding 3 months was protective against mortality versus no exposure: odds ratio (OR) for exposure of less than 1 year, 0.08 (95% confidence interval [CI], 0.03-0.23); OR for exposure of 1 year or longer, 0.09 (95% CI, 0.06-0.13). Methotrexate was protective against mortality only with exposure for 1 year or longer (OR, 0.08; 95% CI, 0.02-0.28). LIMITATIONS: Observational studies are subject to unmeasured confounding. CONCLUSIONS: Biologic therapy was associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration; methotrexate reduced risk only with exposure for 1 year or longer.
引用
- Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis. J Am Acad Dermatol. 2020. PMID: 32798580. doi:10.1016/j.jaad.2020.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。